174 related articles for article (PubMed ID: 12052139)
1. Pharmacogenetics and folate metabolism -- a promising direction.
Ulrich CM; Robien K; Sparks R
Pharmacogenomics; 2002 May; 3(3):299-313. PubMed ID: 12052139
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of folate-related drug targets in cancer treatment.
Robien K; Boynton A; Ulrich CM
Pharmacogenomics; 2005 Oct; 6(7):673-89. PubMed ID: 16207145
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
Dervieux T; Greenstein N; Kremer J
Arthritis Rheum; 2006 Oct; 54(10):3095-103. PubMed ID: 17009228
[TBL] [Abstract][Full Text] [Related]
4. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
6. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
7. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
8. How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
Jennings BA; Willis G
Cancer Lett; 2015 Jan; 356(2 Pt A):224-30. PubMed ID: 24614284
[TBL] [Abstract][Full Text] [Related]
9. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
De Mattia E; Toffoli G
Eur J Cancer; 2009 May; 45(8):1333-51. PubMed ID: 19144510
[TBL] [Abstract][Full Text] [Related]
10. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
11. Cellular aspects of folate and antifolate membrane transport.
Brzezińska A; Wińska P; Balińska M
Acta Biochim Pol; 2000; 47(3):735-49. PubMed ID: 11310973
[TBL] [Abstract][Full Text] [Related]
12. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacogenetics of methotrexate.
Castaldo P; Magi S; Nasti AA; Arcangeli S; Lariccia V; Alesi N; Tocchini M; Amoroso S
Curr Drug Metab; 2011 Mar; 12(3):278-86. PubMed ID: 21470106
[TBL] [Abstract][Full Text] [Related]
14. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Walters CL; Arend RC; Armstrong DK; Naumann RW; Alvarez RD
Gynecol Oncol; 2013 Nov; 131(2):493-8. PubMed ID: 23863359
[TBL] [Abstract][Full Text] [Related]
15. Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al.
Ranganathan P
Arthritis Rheum; 2006 Oct; 54(10):3372; author reply 3372-3. PubMed ID: 17009311
[No Abstract] [Full Text] [Related]
16. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics.
Meshkin B; Blum K
Drug Metab Lett; 2007 Jan; 1(1):55-60. PubMed ID: 19356019
[TBL] [Abstract][Full Text] [Related]
17. 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease.
Kim YI
Nutr Rev; 2005 Nov; 63(11):398-407. PubMed ID: 16370225
[TBL] [Abstract][Full Text] [Related]
18. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of drug-induced birth defects: what is known so far?
Wilffert B; Altena J; Tijink L; van Gelder MM; de Jong-van den Berg LT
Pharmacogenomics; 2011 Apr; 12(4):547-58. PubMed ID: 21521026
[TBL] [Abstract][Full Text] [Related]
20. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
